A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2002
10/23/2002	EP1250441A1 Ceramidase
10/23/2002	EP1250438A2 Therapeutic polypeptides and methods for using same
10/23/2002	EP1250436A1 Toll-like receptor
10/23/2002	EP1250434A2 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
10/23/2002	EP1250433A1 Human membrane proteins and polynucleotides encoding the same
10/23/2002	EP1250432A2 Nuclear hormone receptors
10/23/2002	EP1250431A2 Modulation of gene expression in formation of fatty atherosclerotic lesions
10/23/2002	EP1250429A2 Human sperm specific lysozyme-like proteins
10/23/2002	EP1250428A1 32164 protein, a novel seven transmembrane protein
10/23/2002	EP1250426A2 Secreted and transmembrane polypeptides and nucleic acids encoding same
10/23/2002	EP1250425A2 Secreted human proteins, polynucleotides encoding them and methods of using the same
10/23/2002	EP1250422A2 Myeloid colony stimulating factor and uses thereof
10/23/2002	EP1250421A1 Recombinant flaviviruses and methods of use thereof
10/23/2002	EP1250358A1 Therapeutic peptides
10/23/2002	EP1250357A1 Myostatin and mimetics thereof
10/23/2002	EP1250355A1 Chimeric prostate-homing peptides with pro-apoptotic activity
10/23/2002	EP1250354A1 Peptide fragments of colostrinin and their use
10/23/2002	EP1250353A2 P21 derived peptides capable of inhibiting cdk/cyclin complexes
10/23/2002	EP1250347A1 Antisense modulation of akt-3 expression
10/23/2002	EP1250157A1 Antisense modulation of inducible nitric oxide synthase expression
10/23/2002	EP1250155A1 Angiogenesis and vascular permeability modulators and inhibitors
10/23/2002	EP1250154A2 G-csf conjugates
10/23/2002	EP1250148A1 Use of fsh for treating infertility
10/23/2002	EP1250147A1 Interferon-alpha use in the treatment of ewing's family of tumors
10/23/2002	EP1250146A2 Use of neurotoxins for treating diabetes
10/23/2002	EP1250145A1 C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
10/23/2002	EP1250137A2 Jak/stat pathway inhibitors and the uses thereof
10/23/2002	EP1250135A1 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
10/23/2002	EP1250134A1 Compositions for the prevention of diaper dermatitis
10/23/2002	EP1250131A2 Modulation of the blood-brain barrier transporter for leptin
10/23/2002	EP1250127A1 A method of administering a medicinal aerosol formulation
10/23/2002	EP1250126A2 Transepithelial delivery of glp-1 derivatives
10/23/2002	EP1250124A2 Slimming cosmetic composition comprising as active agent a plant extract containing a plant natriuretic peptide (pnp)
10/23/2002	EP1250095A1 Versatile hydrophilic dyes
10/23/2002	EP1250055A1 Immune modulation with death receptor-induced apoptosis
10/23/2002	EP1179012B1 Long lasting fusion peptide inhibitors of viral infection
10/23/2002	EP1154784B1 Therapeutically active mixture of substances containing s-acetylglutathione and aciclovir
10/23/2002	EP1150702B1 Use of orosomucoid for the production of a pharmaceutical preparation for the treatment of pancreatitis
10/23/2002	EP1144009B1 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
10/23/2002	EP1061943B1 Use of fgf-5 polypeptides for preventing the death of retinal neurons and treating ocular diseases
10/23/2002	EP0948255A4 Improved chondrogenic differentiation of human mesenchymal stem cells
10/23/2002	EP0918533B1 Anti-chlamydial methods and materials
10/23/2002	EP0858345B1 Use of muteins of wild-type cytokines as immunogens
10/23/2002	EP0826000B1 Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
10/23/2002	EP0766745B1 Monoclonal antibody specific for human 4-1bb and cell line producing same
10/23/2002	EP0750510B1 Anti-acne skin treatment composition
10/23/2002	EP0723552B1 Oligopeptides derived from c-reactive protein fragments
10/23/2002	EP0721470B1 Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer
10/23/2002	EP0576623B1 Binding domains in notch and delta proteins
10/23/2002	CN1376197A Use of a recombinant defective adenovirus comprising a nucleic acid encoding an angiogenic factor for treating pulmonary hypertension
10/23/2002	CN1376166A Peptide that lower blood glucose levels
10/23/2002	CN1376165A Materials and methods for inhibition of Lg E production
10/23/2002	CN1376164A Gcsf缀合物 Gcsf conjugates
10/23/2002	CN1376163A Highly purified cytokine activating factor and methods of use
10/23/2002	CN1376162A Novel techykinin peptides, precursor peptides thereof and genes encoding the same
10/23/2002	CN1376143A Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient
10/23/2002	CN1376072A Metabolic intervention with GLP-1 or its biologically active analygues to improve the function of the ischemic and reperfused brain
10/23/2002	CN1376071A Anti cancer agent and method of treatment of cancer
10/23/2002	CN1376070A Method for the therapeutic management of extrauterine prolifieration of endometrical tissue, chronic pelvic pain and fallopian tube obstruction
10/23/2002	CN1376067A Conditioned cell culture medium compositions and method of use
10/23/2002	CN1376062A Use of amino acids for making medicine for treating to insulin-resistance
10/23/2002	CN1375503A Androgen receptor compound relative protein
10/23/2002	CN1375502A Polyglycol modified recombinant human interferon
10/23/2002	CN1375501A New osteoclast formation inhibiting factor and its coding sequence and use
10/23/2002	CN1375500A Thymic peptide fusion protein as one new interferon and its prepn. and use
10/23/2002	CN1375332A Composition and method for making Akt cancer gene inactivate and activating P38 precell fade-out gene
10/23/2002	CN1093175C New structure L-asparaginase engineering bacterium and its fermented culture
10/23/2002	CN1092990C Modulation of cell proliferation and wound healing
10/23/2002	CN1092938C Diabetic supplement bar
10/23/2002	CA2383149A1 Process for partially reducing or eliminating the symptoms associated with the release of histamine in the body
10/23/2002	CA2383115A1 Use of an effective amount of at least one ion chelating agent to enhance the tolerance level of sensitive or intolerant skin
10/22/2002	US6469207 Hiv protease inhibitors; administering to treat aids (acquired immune deficiency syndrome)
10/22/2002	US6469158 Synthesis, deprotection, analysis and purification of RNA and ribozymes
10/22/2002	US6469155 HIgR and related domain which binds glycoprotein D of herpes simplex virus
10/22/2002	US6469152 Flea allantoinase nucleic acid molecules, proteins and uses thereof
10/22/2002	US6469144 Apo-2li (apo-2 ligand inhibitor, related to apoptosis) monoclonal antibodies
10/22/2002	US6469143 Antigen/antibody specificity exchanger
10/22/2002	US6469142 Components of nmda receptors that have cation-selective channels and bind glutamate and nmda (n-methyl-d-aspartate)
10/22/2002	US6469138 Thrombospondin receptor binding peptides
10/22/2002	US6469137 Myelopeptides and their therapeutic use
10/22/2002	US6469055 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor
10/22/2002	US6469045 Thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products; oral administration
10/22/2002	US6469036 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/22/2002	US6469029 Azacycloalkanone serine protease inhibitors
10/22/2002	US6469024 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
10/22/2002	US6468986 Composition comprising polynucleotide and polycationic agent which exhibits net positive electrical charge at physiological ph, and is capable of mediating entry of polynucleotides into cell
10/22/2002	US6468985 Administering nucleic acid molecule encoding retinoblastoma protein-interacting zinc finger protein at or adjacent to site of tumor, wherein protein comprises specified amino acid sequence and is expressed in tumor cell and reduces its growth
10/22/2002	US6468983 RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
10/22/2002	US6468978 Conjugate comprising 1 to 4 moieties covalently bound to polypeptide comprising hedgehog n-terminal domain, each being polypeptide containing 10 to 30 hydrophobic amino acids or positively charged amino acids forming transmembrane helices
10/22/2002	US6468977 Compounds useful in treatment treatment of disorder and/or disease caused by activity of enzymes such as human rhinovirus 3c protease, transglutaminase and cathepsins
10/22/2002	US6468976 Monohydrate lisinopril
10/22/2002	US6468974 Oligopeptides that provide desirable in vitro and in vivo growth hormone releasing activity and have at least one other desirable biological activity such as increased retention time
10/22/2002	US6468973 Method in the treatment of schizophrenia
10/22/2002	US6468972 Method to promote, stimulate and/or delay hair loss by a brady kinin antagonist
10/22/2002	US6468970 Analogs of NT-3
10/22/2002	US6468969 Inhibition of HIV-1 replication using d-amino acid peptides
10/22/2002	US6468968 Comprising a cyclosporin in a carrier medium of a fatty acid triglyceride and a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester; biavailability; side-effect reductions
10/22/2002	US6468967 Methods for administration of antibiotics
10/22/2002	US6468966 Octacyclodepsipeptides having an endoparasiticidal action
10/22/2002	US6468965 Pharmaceutical composition for oral administration of a mixture of chelating agents

1 ... 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 ... 3163